NYSE$ANVS

Annovis Bio · Q2 2025 earnings

Q2 2025 earnings · · Before market open · Investor relations

Briefing

Annovis Bio reported Q2 2025, net loss of $6.2M.

For Q2 2025, Annovis Bio reported a net loss of $6.2M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.

  • Net loss $6.2M.
  • Annovis Bio highlights operating priorities and capital allocation.
  • Annovis Bio highlights operating priorities and capital allocation.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.32

Previous: -$0.44+27.3%
G&A Expenses

$1.11M

No prior period
Other Income (Net)

$51.4K

No prior period
Diluted EPS Loss

$0.32

No prior period
Avg Shares (Diluted)

19.5M

No prior period
Interest Income

$191K

No prior period
Warrant Fair Value Change

-$140K

No prior period
Basic EPS

$0.32

No prior period
Basic Shares Outstanding

19.5M

No prior period
R&D Expenses

$5.16M

No prior period
Total Operating Expenses

$6.27M

No prior period
Net Income

-$6.22M

Previous: -$5.02M-23.9%
Operating Income

-$6.27M

Previous: -$7.76M+19.2%

Revenue & EPS history

Annovis Bio · Revenue · Quarterly

$0

Q2 2025

Forward guidance

The release discusses Annovis Bio's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.

Tailwinds

  • Annovis Bio cites demand and execution supporting the near-term outlook.
  • Liquidity and balance-sheet capacity support operations and shareholder returns.

Headwinds

  • GAAP profitability remained under pressure in Q2 2025.
  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect comparability versus prior periods.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

-1.9%

Avg return

Earnings day

+0.2%

Avg return

5 days after

+8.0%

Avg return

30 days after

35%

9 / 26 earnings

Positive

+41.0%

Q1 2024

Best reaction

-68.5%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.1%-7.0%-16.8%
Q4 2025-3.1%-8.1%-37.1%
Q3 2025+15.5%+43.6%+95.7%
Q2 2025-1.4%-2.8%-15.2%
Q1 2025+6.6%+18.9%+66.3%
Q4 2024-7.1%-8.5%+14.2%
Q3 2024-7.6%-16.2%-27.0%
Q2 2024+9.9%+14.9%+3.2%
Q1 2024+41.0%+40.1%+2.5%
Q4 2023-6.1%-6.7%-48.7%
Q3 2023-0.3%+3.1%+76.9%
Q2 2023-1.7%-3.5%-17.0%
Q1 2023-5.8%-8.5%-9.1%
Q4 2022-22.5%-18.2%-4.9%
Q3 2022-4.1%+1.1%-3.3%
Q2 2022+5.9%+10.1%-7.1%
Q1 2022+9.9%-3.3%-1.3%
Q4 2021-7.6%-13.5%+1.0%
Q3 2021-0.9%+21.3%-30.4%
Q2 2021-68.5%-65.8%-66.2%
Q1 2021+5.8%+30.1%+188.3%
Q4 2020-10.3%-9.7%-0.5%
Q3 2020+3.8%-1.1%+28.7%
Q2 2020-0.3%-2.2%-20.6%
Q1 2020-0.8%-3.0%+21.9%
Q4 2019+6.5%+0.9%+14.1%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro